UFMylation: An integral post-translational modification for the regulation of proteostasis and cellular functions

Wang, Xiaohui; Lv, Xiaowei; Ma, Jingjing; Xu, Guoqiang

doi:10.1016/j.pharmthera.2024.108680

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article1

Preprint1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications

Xia,

Mei,

Huang

et al. 2025

Translational Oncology

View full text Add to dashboard Cite

O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications

Xia,

Mei,

Huang

et al. 2025

Translational Oncology

View full text Add to dashboard Cite

Identification and characterization of UBA5 inhibitors

Singh,

Wan,

Ahmed

et al. 2024

Preprint

View full text Add to dashboard Cite

UBA5 is a critical E1-activating enzyme in the UFMylation pathway, a post-translational modification process implicated in neurodegenerative diseases and cancers. In this study, we developed a high-throughput screening (HTS) assay to identify inhibitors of UBA5 from a library of blood-brain barrier (BBB)-permeable compounds. The assay, based on the AMP-Glo™ kit, enabled the identification of five novel UBA5 inhibitors belonging to three distinct chemical scaffolds with low micromolarIC50values. These inhibitors demonstrated selectivity for UBA5 over other E1 enzymes, such as UBA1, and showed efficacy in inhibiting endogenous UFMylation in HEK293T cells. The identified inhibitors not only provided valuable tools for studying UFMylation but also represent potential therapeutic candidates for diseases associated with dysregulated UFMylation, such as Alzheimer’s disease and cancer. Further optimization of these compounds is necessary to enhance their potency and pharmacokinetic properties. Our findings highlight UBA5 as a promising therapeutic target and pave the way for the development of selective inhibitors that can modulate UFMylation in human diseases.

show abstract

UFMylation: An integral post-translational modification for the regulation of proteostasis and cellular functions

Cited by 2 publications

References 110 publications

O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications

O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications

Identification and characterization of UBA5 inhibitors

Contact Info

Product

Resources

About